A Randomized, Sponsor-Open, Investigator-Blind, Subject-Blind, Placebo-Controlled, Single Ascending Dose, to Investigate the Safety, Tolerability and Pharmacokinetics of RO7062931 Following Subcutaneously Administration in Healthy Chinese Volunteers
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs RO 7062931 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 25 Jul 2019 Status changed from recruiting to completed.
- 22 Apr 2019 Planned End Date changed from 2 May 2019 to 4 Jul 2019.
- 22 Apr 2019 Planned primary completion date changed from 2 May 2019 to 4 Jul 2019.